Compass Pathways Reports Positive Phase 3 Data on COMP360 for Treatment-Resistant Depression

Compass Pathways (NASDAQ:CMPS) reported positive 26-week results from Part B of its Phase 3 COMP006 trial evaluating COMP360, a synthetic psilocybin therapy combined with psychological support. The data showed sustained clinical benefits for treatment-resistant depression and reinforced the company's regulatory outlook ahead of an expected NDA submission in Q4.

By Laiba Immad Wed, July 15, 2026 at 12:22 PM GMT+3 2 min read · Yahoo Finance · July 15, 2026, 09:22 UTC

Tickers: $CMPS

Topics: Biotechnology Mental Health Pharmaceuticals Psychedelics

Read the full article at Yahoo Finance

More World news

Mercury Insurance Issues Safety Guidelines for Portable Generator Use During Power Outages PR Newswire · November 12, 2026, 14:06 UTC
Paratus Appoints New Senior Leadership to Drive Expansion into Asset-Backed Optimisation PR Newswire · November 12, 2026, 14:03 UTC
Transamerica Partners with Congruent Solutions to Modernize Retirement Plan Payroll Administration PR Newswire · November 12, 2026, 14:00 UTC
Kindo Raises $57.6 Million Total to Scale Enterprise AI Agent Management Platform PR Newswire · November 12, 2026, 14:00 UTC
Texans Credit Union Introduces Cash Back Checking and Ignite Youth Banking Suite PR Newswire · November 12, 2026, 14:03 UTC
Apple Announces Preorders for Select Smart Home Collection Accessories The Verge · November 12, 2026, 14:00 UTC
SolaREIT Surpasses $8.5 Billion Milestone in Clean Energy Land Financing PR Newswire · November 12, 2026, 14:00 UTC
Avalara Launches Native 1099 E-Filing Integration for Workday Financial Management PR Newswire · November 12, 2026, 14:00 UTC
Rocket Companies Appoints Datadog COO Adam Blitzer to Board of Directors PR Newswire · November 12, 2026, 14:00 UTC
ALKEME Insurance Announces 'ALKEME Bowl' Sponsorship of Arizona vs. Utah College Football Matchup PR Newswire · November 12, 2026, 14:00 UTC